What AI says about Eteplirsen

EXONDYS 51 is the first FDA-approved treatment for Duchenne muscular dystrophy in patients with a confirmed genetic mutation treatable by skipping exon 51. The therapy works by helping some patients produce a shorter form of the dystrophin protein, a marker considered likely to predict clinical benefit.